The Injectable Contraceptive Medroxyprogesterone Acetate Attenuates Mycobacterium tuberculosis-Specific Host Immunity Through the Glucocorticoid Receptor. by Tomasicchio, Michele et al.
LSHTM Research Online
Tomasicchio, Michele; Davids, Malika; Pooran, Anil; Theron, Grant; Smith, Liezel; Semple, Lynn;
Meldau, Richard; Hapgood, Janet Patricia; Dheda, Keertan; (2018) The injectable contraceptive
Medroxyprogesterone Acetate attenuates Mycobacterium tuberculosis-specific host immunity through
the Glucocorticoid receptor. The Journal of infectious diseases, 219 (8). pp. 1329-1337. ISSN 0022-
1899 DOI: https://doi.org/10.1093/infdis/jiy657
Downloaded from: http://researchonline.lshtm.ac.uk/4653176/
DOI: https://doi.org/10.1093/infdis/jiy657
Usage Guidlines:
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
The Journal of Infectious Diseases
MPA Increases Mtb Pathogenesis • JID 2019:219 (15 April) • 1329
The Injectable Contraceptive Medroxyprogesterone 
Acetate Attenuates Mycobacterium tuberculosis–Specific 
Host Immunity Through the Glucocorticoid Receptor
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Background.  The effects of the widely used progestin-only injectable contraceptives, medroxyprogesterone acetate (MPA) and 
norethisterone acetate (NET-A), on host susceptibility to Mycobacterium tuberculosis (Mtb) are unknown.
Methods. We recruited human immunodeficiency virus–uninfected females, not taking any contraceptives, from Cape Town, 
South Africa, to evaluate the effect of MPA, NET-A, and dexamethasone on Mtb containment in monocyte-derived macrophages 
co-incubated with purified protein derivative (PPD)–driven peripheral blood–derived effector cells.
Results. MPA (P  <  .005) and dexamethasone (P  <  .01), but not NET-A, significantly attenuated Mtb containment in Mtb-
infected macrophages co-cultured with PPD-driven effector cells at physiologically relevant concentrations and in a dose-dependent 
manner. Antagonizing the glucocorticoid receptor with mifepristone (RU486) abrogated the reduction in Mtb containment. In 
PPD-stimulated peripheral blood mononuclear cells, MPA and dexamethasone, but not NET-A, upregulated (median [interquartile 
range]) regulatory T cells (5.3% [3.1%–18.2%]; P < .05), reduced CD4+ T-cell interferon-γ (21% [0.5%–28%]; P < .05) and granzyme 
B production (12.6% [7%–13.5%]; P < .05), and reduced CD8+ perforin activity (2.2% [0.1%–7%]; P < .05). RU486 reversed regula-
tory T-cell up-regulation and the inhibitory effect on Th1 and granzyme/perforin-related pathways.
Conclusions. MPA, but not NET-A, subverts mycobacterial containment in vitro and downregulates pathways associated with 
protective CD8+- and CD4+-related host immunity via the glucocorticoid receptor. These data potentially inform the selection and 
use of injectable contraceptives in tuberculosis-endemic countries.
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Tuberculosis (TB) is the biggest infectious disease killer glob-
ally and remains out of control in several regions of the world 
[1]. It has been estimated that in 2016, 10.4 million people were 
living with the disease worldwide and 1.3 million died [2]. The 
disease pathogenesis remains poorly understood. There are sev-
eral drivers of TB, including poverty, poor nutrition, human 
immunodeficiency virus type 1 (HIV-1) co-infection, exposure 
to biomass fuel combustion, smoking, diabetes, and use of glu-
cocorticoids, among others [1]. However, one widely used and 
common exposure that has been poorly studied as a potential 
driver of TB is the use of injectable contraceptives.
The injectable progestin-only contraceptives medroxyprogester-
one acetate (MPA) (Depo-Provera; administered every 3 months) 
and norethisterone enanthate or norethisterone acetate (NET-EN 
and NET-A, respectively; administered every 2 months), are ex-
tensively used in Sub-Saharan Africa (16.5 million users in 2015), 
where infectious diseases such as Mycobacterium tuberculosis 
(Mtb) are endemic [3, 4] and TB is the highest cause of maternal 
mortality [5]. For example, in KwaZulu-Natal, South Africa, up to 
82% of women in rural settings are on an injectable progestin-only 
contraceptive compared with 15% on oral contraceptives [6]. Even 
though MPA and NET-A are designed to act via the progesterone 
receptor (PR), MPA, unlike NET-A, acts as an agonist for the 
glucocorticoid receptor (GR) [7–10], the activation of which is a 
well-known risk factor and trigger for TB reactivation [11, 12]. 
Indeed, the GR regulates a number of genes that are important for 
TB-related immunity (reviewed in [13]). These considerations are 
particularly relevant in South Africa, where injectable contracep-
tive usage is high and TB is widespread.
A recent meta-analysis of clinical observational data suggested 
that MPA is associated with a significant 40% increase in risk for 
HIV-1 acquisition, whereas no such association has been found 
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with limited data for NET-A [14]. There is evidence for several 
possible mechanisms for this effect of MPA, including inhibition 
of immune function [4] and increased HIV-1 replication in target 
cells [15]. However, very little is known regarding how hormonal 
contraceptives affect Mtb pathogenesis. In mice, MPA increases 
Mtb bacterial load in the lung [16], but whether a similar effect 
occurs in humans remains unknown. This is an important question 
as, at population level, it could represent a major modifiable risk 
factor that could impact TB control in endemic countries. Thus, we 
sought to determine whether MPA and/or NET-A diminishes the 
ability of effector cells to contain Mtb in vitro, whether they modu-
late pathways associated with protective host immunity against TB, 
and whether these effects are regulated via the GR.
METHODS
Study Site and Population
We recruited healthy HIV-1-uninfected contraceptive-free 
women (n = 11) from Cape Town, South Africa. Patients who 
were recruited to the study had not used a contraceptive for 
≥3 months prior to recruitment. Written informed consent was 
obtained from all participants. Approximately 100 mL of blood 
was obtained from each volunteer by a phlebotomist. Ethical 
approval was obtained from the Research Ethics Committee at 
the University of Cape Town, South Africa (307/2014).
Isolation and Culture of Peripheral Blood Mononuclear Cells
Peripheral blood mononuclear cells (PBMCs) were isolated 
by density centrifugation using Leucosep tubes (Greiner) and 
Histopaque-1077 (Sigma), according to the manufacturer’s 
specifications. Cells were cultured in Roswell Park Memorial 
Institute medium (RPMI) containing 10% human A/B serum 
(Western Province blood transfusion services, South Africa), 
100 IU penicillin/streptomycin, 2  mM l-glutamine, 25  mM 
HEPES, and 0.1 mg/mL sodium pyruvate (R-10).
Mycobacterial Containment Assays
The mycobacterial containment assays were performed as 
described previously [17]. In brief, effector cells were generated 
by incubating PBMCs (2 × 105 cells/well) in 96-well round-bot-
tom tissue culture plates (Greiner) with or without or in combi-
nation with 12 µg/mL purified protein derivative (PPD) (Statens 
Serum Institut), dexamethasone, MPA, and NET-A (which 
is metabolized to NET) (Sigma) at concentrations of 10  nM, 
50 nM, 100 nM, and 1 µM for 3 days at 37°C. The stock concen-
trations of dexamethasone, MPA, NET-A, and RU486 (mifepri-
stone) were prepared in 100% ethanol. These compounds are 
soluble in the growth medium at concentrations ≤1 µM. One-
half volume of fresh medium was added containing 10 U/mL 
interleukin (IL-) 2 (Roche), and the cells were incubated for an 
additional 4 days at 37°C. IL-2 was added to support the viabil-
ity and proliferation of the PBMCs. Dexamethasone, a synthetic 
GR agonist, was included in the study as a control to determine 
the maximal GR-dependent response in both the containment 
and flow cytometry assays. For the antagonist studies, 100 nM 
of dexamethasone, MPA, or NET-A was used in conjunction 
with 1 µM of the GR and progesterone receptor (PR) antagonist 
RU486 (Sigma).
In parallel with deriving the effector cells, monocyte-derived 
macrophages (MDMs; 2 ×  106 cells/well) were generated and 
infected with a multiplicity of infection (MOI) of one Mtb H37Rv 
to one MDM (MOI = 1:1). After 18 hours of incubation at 37°C, 
the cells were washed to remove extracellular Mtb. The effector 
cells were co-cultured with Mtb-infected macrophages and the 
cells were incubated at 37°C for 24 hours. The cells were then 
washed, and lysed in water, and various dilutions were plated 
onto Middlebrook 7H10 agar (Merck) supplemented with 10% 
oleic albumin dextrose catalase (OADC; Becton Dickinson) sup-
plement. After 10–14 days of incubation at 37°C, colony-form-
ing units (CFUs) were counted and expressed as CFU/mL. The 
percentage (%) mycobacterial containment was calculated rela-
tive to the reference control (Mtb-infected MDMs only): 
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Flow Cytometric Determination of Regulatory T-Cell Expansion, 
Interferon-γ Expression, and Cytotoxic T-Lymphocyte Induction In Vitro
PBMCs (2 × 106 cells) were treated with 12 µg/mL PPD, 100 nM 
dexamethasone, MPA, NET-A, and/or 1 µM RU486 for 7 days 
at 37°C. After 7 days, cells were stained with antibodies against 
CD3, CD4, CD8, CD25, FOXP3, interferon gamma (IFN-γ) 
(Biolegend), granzyme B, and perforin (Becton Dickinson).
Approximately 1 × 105 cells were acquired using a LSRII Flow 
Cytometer (Becton Dickinson), and the data were analyzed 
using FloJo software version 10.1 (TreeStar). Dead cells were 
excluded from the scatterplots prior to analysis, and negative 
gates were set using fluorescence minus one controls. Only the 
single cellular population was analyzed.
Statistical Analysis
Data were analyzed for statistical significance by one-way anal-
ysis of variance with Dunnett post test or Wilcoxon signed-rank 
paired t test using GraphPad Prism software version 6.0. For 
dose-response analysis, a nonparametric statistical trend test 
was performed across the concentration range for each com-
pound, using the Wilcoxon signed-rank paired t test, as further 
extended by Cuzick [18], using Stata version 13 software.
RESULTS
MPA, but Not NET-A, Decreases Peripheral Effector-Mediated Mtb 
Containment In Vitro in a Dose-Dependent Fashion
To determine if MPA affects Mtb pathogenesis, we used a myco-
bacterial containment assay. In brief, PBMCs were incubated 
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with or without or in combination with 12 µg/mL PPD, 100 nM 
dexamethasone, MPA, and NET-A for 7 days at 37°C to generate 
the effector cells. The effector cells were co-cultured with Mtb-
infected MDMs for 24 hours at 37°C, and the number of CFUs/
mL was determined by counting colonies on Middlebrook 
7H10 agar containing OADC supplement.
The absolute CFUs showed a significant increase (to simi-
lar levels as Mtb-infected MDMs incubated in the absence of 
PBMCs [MDM-only control: 7.4 × 104 CFU/mL] or in the pres-
ence of PBMCs that were not stimulated with PPD [8.8 × 104 
CFU/mL]) when Mtb-infected MDMs were co-incubated with 
PBMCs that were stimulated with PPD and MPA (1 × 105 CFU/
mL; P < .005) or PPD and dexamethasone (8.7 × 104 CFU/mL; 
P <  .01) compared to PPD and NET-A (5 × 104 CFU/mL) or 
PPD only (2.8 × 104 CFU/mL) (Figure 1A).
We further expressed the data as percentage of Mtb contain-
ment, which is defined as the percentage change in CFU/mL 
relative to the MDM-only control (Figure 1B). The control thus 
represents 0% Mtb containment or 100% survival. Similarly, the 
data showed that PBMCs incubated with PPD and dexametha-
sone (P < .01) or PPD and MPA (P < .005) significantly decreased 
the percentage of Mtb containment compared with PBMCs stim-
ulated with PPD alone (Figure 1B). The MPA-mediated (P < .01) 
decrease in percentage of Mtb containment was not observed 
with PBMCs stimulated with PPD and NET-A. The reduction 
in Mtb containment cannot be explained by dexamethasone or 
MPA reducing the viability of the effector cells more than NET-A, 
because at the time of co-culture with the Mtb-infected MDMs, 
the levels of effector cells that were alive were similar for all the 
treatments as assessed by Trypan blue staining (data not shown).
The synthetic GR agonist dexamethasone, and MPA, unlike 
NET-A, dose-dependently decreased PPD effector-mediated 
Mtb containment within MDMs in vitro (Figure 1C). The levels 
of dose-dependent containment observed with dexamethasone 
were higher than MPA, suggesting that MPA was acting as a 
partial agonist for the GR. Importantly, MPA reduced PPD-
mediated effector containment of Mtb at physiological concen-
trations between 10 nM and 100 nM (P < .01). This reduction in 
containment was not observed with NET-A even at concentra-
tions as high as 1 µM. Complete abolishment of Mtb contain-
ment to similar levels of the reference control were observed 
at MPA concentrations between 10  nM and 1  µM, with the 
highest loss of containment observed at 100 nM (Figure 1C). 
Statistically significant trends [18] were observed for dexameth-
asone (P  <  .0001) and MPA (P  <  .0001), but not for NET-A, 
showing decreased Mtb containment with increasing concen-
trations of compound (Figure 1C).
MPA Reduces PPD-Mediated Effector Mtb Containment Through a 
Mechanism Involving the GR In Vitro
Having shown that MPA can reduce PPD-mediated effec-
tor Mtb containment in a dose-dependent manner like the 
synthetic GR agonist dexamethasone, we wanted to determine 
if the reduction in Mtb containment involved the GR. In brief, 
effector cells were generated as indicated above with or without 
or in combination with 12  µg/mL PPD, 100  nM dexametha-
sone, MPA, NET-A, and/or the GR antagonist RU486 (1 µM). 
The effector cells were co-cultured with Mtb-infected MDMs 
and CFUs/mL were counted as indicated in the methods. As 
we observed previously, the absolute number of CFUs (to sim-
ilar levels as Mtb-infected MDMs incubated in the absence of 
effector cells [8.8  ×  104 CFU/mL]) were significantly higher 
when Mtb-infected MDMs were co-cultured with PPD and 
dexamethasone (8.6 × 104 CFU/mL; P < .05) or PPD and MPA 
(1.02 × 105 CFU/mL; P < .05; but not PPD and NET-A [48 CFU/
mL]) stimulated effector cells compared to when effector cells 
were stimulated with PPD alone (3 × 104 CFU/mL; Figure 2A). 
Importantly, when the Mtb-infected MDMs were co-cultured 
with PPD, dexamethasone, and RU486 (a GR agonist; 2.9 × 104 
CFU/mL) or PPD, MPA, and RU486 (3 ×  104 CFU/mL), the 
number of CFUs were similar to when effector cells were stim-
ulated with PPD only (3 × 104 CFU/mL), indicating that MPA 
and dexamethasone were reducing PPD-mediated effector con-
trol of Mtb through a GR mechanism in vitro (Figure 2A).
As expected, when we represented the data as percentage 
of Mtb containment (as described previously), we observed 
that both dexamethasone (P < .01) and MPA (P < .01), but not 
NET-A, decreased PPD effector-mediated percentage of Mtb 
containment (Figure 2B). In the presence of RU486, the MPA- 
(P < .05) and dexamethasone-mediated decrease in percentage 
containment was reversed (Figure 2B). The data presented here 
indicate that the reduced levels of containment observed with 
MPA involve a GR mechanism.
MPA, but Not NET-A, Increases Regulatory T-Cell Expansion In Vitro
The data presented thus far indicate that MPA, but not NET-
A, reduces Mtb containment through the GR. Next, we wanted 
to determine if the reduction in containment was as a result of 
immune dysfunction in vitro. PPD-generated effector cells in 
the presence of the various contraceptives were evaluated for 
the expansion of regulatory T-cells (Tregs) by flow cytometry. 
Figure 3 shows that in the presence of PPD and MPA (median, 
5.3%; interquartile range [IQR], 3.1%–18.2%), the levels of 
Tregs were upregulated approximately 2-fold above cells treated 
with PPD only (median, 2.8%; IQR, 3.1%–18.2%; P < .05). No 
increase in MPA-mediated Treg expansion was observed in 
the presence of the GR antagonist RU486, and no increase was 
observed when the cells were treated with PPD, dexametha-
sone, NET-A, and/or RU486.
MPA, but Not NET-A, Downregulates PPD-Mediated IFN-γ Expression and 
Cytotoxic T-Lymphocyte Induction in T Cells Involving the GR
Next, we wanted to determine the effect of MPA on IFN-γ 
expression and cytotoxic T-lymphocyte (CTL) induction, in 
1332 • JID 2019:219 (15 April) • Tomasicchio et al
H37Rv infected MDMs
Eector cells
PPD
Dex
MPA
NET-A
A B
C
3×105
2×105
1×105
0
C
FU
/m
L
**
**
**
***
***
ANOVA P = .009 ANOVA P = .0001
+ + + + + +
– + + + + +
– – + + + +
– – – + – –
– – – – + –
– – – – – +
H37Rv infected MDMs
Eector cells
PPD
Dex
MPA
NET-A
–200
–180
–160
–140
–120
–100
–80
–60
–40
–20
–9 –8 –7 –6 –5
0
20
40
60
80
–150
–100
–50
0
50
100
+ + + + +
+ + + + +
– + + + +
– – + – –
– – – + –
– – – – +
Pe
rc
en
ta
ge
 (%
) M
tb
 c
on
ta
in
m
en
t
Pe
rc
en
ta
ge
 (%
) M
tb
 c
on
ta
in
m
en
t
**
*****
***
PPD + Dex ****
PPD + MPA ****
PPD + NET-A
Concentration of test
compound (Log, M)
Figure  1. Medroxyprogesterone acetate (MPA), but not norethisterone acetate (NET-A), decreases peripheral effector cell–mediated Mycobacterium tuberculosis 
(Mtb) containment in vitro. Mtb-infected monocyte-derived macrophages (MDMs) were incubated alone (n = 11) or co-cultured with peripheral blood mononuclear cells 
that were incubated without (n = 10) or with (n = 11) 12 µg/mL purified protein derivative (PPD) alone and in parallel with physiologically representative concentrations of 
dexamethasone (n = 9), MPA (n = 11), or NET-A (n = 9). A, The number of colony-forming units/mL was determined by counting colonies on Middlebrook H9/OADC agar. 
B, Percentage of mycobacterial containment in the presence of 12 µg/mL PPD alone or in combination with 100 nM dexamethasone, MPA, or NET-A (error bars represent 
median and interquartile range). The percentage of containment was calculated relative to the reference control (Mtb-infected MDMs only); the dotted line represents 
relative levels of containment by the reference control (Mtb-infected MDMs only, no Mtb containment). C, Dose-dependent levels of percentage of mycobacterial con-
tainment in the presence of PPD and increasing concentrations of dexamethasone, MPA, and NET-A (a figure greater than –100 indicates proliferation of the organism; 
error bars represent mean and standard deviation). A nonlinear fit of the dose response was performed for MPA and dexamethasone. Data were analyzed for statistical 
significance by one-way analysis of variance withDunnett post test or Wilcoxon signed-rank paired t test, where **, *** and **** indicate P < .01, P < .005 and P < 
.0001, respectively. Statistical trend analysis for each dose response was performed by the Wilcoxon signed-rank paired t test, as further extended by Cuzick [18], and 
showed a significant trend only for dexamethasone (P < .0001) and MPA (P < .0001). Abbreviations: ANOVA, analysis of variance; CFU, colony-forming units; Dex, dexa-
methasone; MDM, monocyte-derived macrophage; MPA, medroxyprogesterone acetate; Mtb, Mycobacterium tuberculosis; NET-A, norethisterone acetate; PPD, purified 
protein derivative.
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CD4+ and CD8+ T cells in vitro (Figure 4). MPA (median, 2.2%; 
IQR, 0.1%–7%; P <  .05), but not NET-A (median, 3.2%; IQR, 
0.07%–12%), had the ability to reduce PPD-induced perforin 
expression (an important cytolytic protein; median, 3.9%; IQR, 
1.08%–11%) in CD8+ T cells. This effect was abrogated in the 
presence of RU486 (median, 3%; IQR, 1.1%–17%), indicating 
that the GR was involved. Similarly, dexamethasone (median, 
1.1%; IQR, 0.1%–3%; P < .05) also reduced perforin induction 
by PPD (median, 3.9%; IQR, 1.08%–11%) in CD8+ T cells, but 
surprisingly this effect was not reversed with RU486 (median, 
1.7%; IQR, 0.6%–3.2%), suggesting that it occurs through a 
GR-independent mechanism (Figure 4A). In contrast, MPA had 
no effect on IFN-γ and granzyme B (a marker for cytotoxicity) 
expression in the CD8+ T cells (Supplementary Figure 1). Our 
data further showed that MPA had no effect on the expression 
of tumor necrosis factor alpha (TNF-α), IL-10, IL-17, CD69, or 
IL-13 in the CD8+ T cells (Supplementary Figure 1).
We further show that MPA (median, 21%; IQR, 0.5%–28%; 
P < .05), but not NET-A (median, 24%; IQR, 3.2%–30%) reduced 
PPD-induced (median, 27%; IQR, 2.8%–35%) expression of 
IFN-γ in CD4+ T cells (Figure 4B). A similar trend was observed 
with dexamethasone (median, 11%; IQR, 0.4%–30%). As was 
observed in the CD8+ T cells, both dexamethasone (median, 
5.1%; IQR, 1.6%–11.6%; P  <  .05) and MPA (median, 12%; 
IQR, 7%–21%; P <  .05), but not NET-A (median, 18.5%; IQR, 
9%–87%), repressed PPD-induced (median, 22.2%; IQR, 13%–
86%) granzyme B expression in the CD4+ T cells (Figure 4B). This 
repression with MPA was reversed with RU486 (median, 18.5%; 
IQR, 6%–87%) in the CD4+ T cells, indicative of a GR-mediated 
mechanism. We observed no differences in the expression of per-
forin, GATA-3, IL-10, TNF-α, CD69, T-box protein expressed in 
T cells (Tbet), IL-17, or IL-13 in the CD4+ T cells stimulated with 
PPD and dexamethasone, PPD and MPA or PPD and NET-A 
(Supplementary Figure 2).
DISCUSSION
We show for the first time that MPA at physiological concen-
trations, but not NET-A, decreases T-cell effector–mediated 
containment of Mtb through a mechanism involving the GR 
in human PBMCs. Furthermore, the decrease in containment 
was associated with increased Treg expansion, decreased IFN-γ 
expression, and reduced CTL induction in vitro.
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Figure 2. Medroxyprogesterone acetate (MPA) decreases peripheral effector Mycobacterium tuberculosis (Mtb) containment through the glucocorticoid receptor (GR). 
Mtb-infected monocyte-derived macrophages (MDMs) were cultured alone (n = 6) or were co-cultured with untreated effector cells (n = 6) or effector cells treated with 12 µg/
mL purified protein derivative (PPD) alone (n = 6); PPD and 100 nM dexamethasone (n = 6); PPD and 100 nM MPA (n = 6); PPD and 100 nM norethisterone acetate (NET-A) 
(n = 6); PPD and 1 µM RU486 (a GR antagonist) (n = 6); PPD, dexamethasone, and RU486 (n = 5); PPD, MPA, and RU486 (n = 6); or PPD, NET-A, and RU486 (n = 6). The relative 
number of colony-forming units/mL (A) was determined as indicated previously. The percentage of mycobacterial containment (B) was determined as indicated previously 
to the reference control (Mtb-infected MDMs only). Error bars represent median and interquartile range. Data were analyzed for statistical significance by one-way analy-
sis of variance with Dunnett post test or Wilcoxon signed-rank paired t test, where * and ** indicate P < .05 and P < .01, respectively. Abbreviations: ANOVA, analysis of 
variance; CFU, colony-forming units; Dex, dexamethasone; MDM, monocyte-derived macrophages; MPA, medroxyprogesterone acetate; Mtb, Mycobacterium tuberculosis; 
NET-A, norethisterone acetate; PPD, purified protein derivative.
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The key finding was that MPA, but not NET-A, decreased Mtb 
containment in vitro (up to 2.6-fold) in a dose-dependent man-
ner. The relative dose-dependent decrease with MPA was lower 
than that produced by dexamethasone, suggesting that MPA was 
acting as a partial agonist for the GR, which is consistent with the 
literature [8, 19, 20]. Remarkably, MPA appeared to decrease the 
levels of Mtb containment at concentrations as low as 10 nM. The 
peak serum concentration (Cmax) of MPA in the peripheral blood 
of women has been reported to range from 3 to 100 nM [21–25], 
while NET reaches a peak concentration of 50 nM [26]. While 
100 nM is higher than most reports for serum MPA Cmax, given 
the high interindividual and interstudy variability in reported Cmax 
values in women [27], responses to 100 nM are most likely indic-
ative of maximal possible effects in vivo. After 2–3 months, the 
levels of MPA decreased to between 2.6 and 21 nM, while the lev-
els of NET-A decreased to 13 nM after 2 months [26]. Our results 
therefore suggest that MPA at physiological concentrations could 
impact TB pathogenesis and drive Mtb replication in the host, 
thus increasing the risk of acquiring active or latent TB infection.
The findings are broadly concordant with murine data indi-
cating that MPA increased Mtb bacterial load in the lungs [16]; 
however, the immune systems of mice vs humans are different 
and direct comparisons are misleading. Another study inves-
tigated the effects of MPA on Mycobacterium bovis bacillus 
Calmette-Guérin (BCG) in human PBMCs [28]. BCG reduces 
IL-1α, IL-12p40, IL-10, IL-13, and granulocyte-colony stimu-
lating factor (G-CSF) levels in vitro. However, all BCG strains 
are missing the region of difference 1 (RD-1) from their genome 
[29, 30], which expresses key Mtb virulence factors [31]. The 
current study is the first to investigate the effects of injectable 
contraceptives on Mtb pathogenesis, the first to investigate the 
anti-mycobactericidal effects of injectable contraceptives in 
human PBMCs, and the first to directly compare the immuno-
pathological effects of 2 different injectable contraceptives.
Our data show that MPA increased Treg expansion in vitro. 
However, in the presence of the GR antagonist RU486, this 
increase was not observed, suggesting that the GR was involved. 
Treg frequency is increased in patients with TB [17] and has 
been shown to downregulate effector functions of CD8+ and 
CD4+ T cells [32], inhibit Th1 effector responses [33], and impair 
the ability of alveolar and monocyte-derived macrophages to 
restrict the growth of Mtb in the presence of effector cells [17]. 
In addition, glucocorticoids have been shown to increase Treg 
expansion in the peripheral blood of asthma patients [34]. Thus, 
our data indicate that MPA could further suppress protective 
immune responses to TB, allowing bacterial persistence.
MPA and dexamethasone, but not NET-A, downregulated 
perforin and granzyme B expression in CD8+ and CD4+ T cells, 
respectively, which was reversed with RU486, suggesting that 
the GR was involved. Others have also shown that glucocorti-
coids downregulate granzyme B and perforin [35]. Our results 
show that MPA is acting like a glucocorticoid in this context. 
It has been documented in human [36] and transgenic mouse 
models [37] that granule-dependent killing of Mtb involving 
granulysin, granzymes, and perforin are essential to lyse and 
kill Mtb-infected cells. Perforin is essential for pore-mediated 
delivery of granzyme B into the cell to induce caspase-depen-
dant apoptosis [38], and a robust CTL response is indispensable 
for human protective host immunity [39]. It is unclear whether 
the effects of MPA are mediated through CD4+ or CD8+ T cells. 
However, we noted changes in IFN-γ and perforin expression, 
all associated with host protection, in both CD4+ and CD8+ 
T cells. While CD4+ T cells are incontrovertibly implicated in 
TB pathogenesis, the role of CD8+ T cells is less clear and sup-
ported largely by murine rather than direct human data [40, 41].
MPA also appeared to reduce expression of IFN-γ in CD4+ 
T cells, crucial for activation of macrophages to eradicate Mtb 
[42]. Collectively, these data indicate that MPA suppresses CTL-
mediated killing of the PPD-activated cells through decreased 
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Figure 3. Medroxyprogesterone acetate (MPA), but not norethisterone acetate 
(NET-A), increases regulatory T-cell (Treg) expansion in vitro, and this is attenuated 
by RU486. Effector cells were generated by incubating peripheral blood mononu-
clear cells with (n = 7) or without (n = 7) 12 µg/mL purified protein derivative (PPD) 
or in combination with 100 nM dexamethasone (n = 6), MPA (n = 7), NET-A (n = 6), 
and/or 1 µM RU486 (n = 6) for 7 days at 37°C. The levels of Tregs were determined 
by flow cytometry. Tregs were classified as CD4+, CD25+, and FOXP3+. Dead cells 
were excluded from the scatterplots prior to analysis, and negative gates were set 
using fluorescence minus one controls. Only the single cellular populations were 
analyzed. Error bars represent median and interquartile range. Data were analyzed 
for statistical significance by one-way analysis of variance with Dunnett post test, 
where * indicates P < .05. Abbreviations: Dex, dexamethasone; MPA, medroxypro-
gesterone acetate; NET-A, norethisterone acetate; PPD, purified protein derivative; 
Treg, regulatory T cell.
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perforin and granzyme B expression, and Th1 activation in vitro, 
thus inhibiting effector function and likely bacterial clearance.
We further report that MPA decreased Mtb containment 
through a mechanism involving the GR. It has been previously 
shown that MPA, but not NET-A, can act as a partial or full 
agonist for the GR [8, 19, 20], and our data are consistent with 
previous reports. While MPA could exert its effects via other 
steroid receptors such as the androgen receptor (AR) and PR [9, 
10], we have previously shown that human PBMCs express the 
estrogen receptor (ER) and mineralocorticoid receptor (MR), 
but no detectable AR or PR [43]. Furthermore, MPA binds 
weakly to the MR [44] and does not bind to the ER [45].
There are a number of limitations to the current study. First, 
the ability of the effector cells to control the bacterium was 
defined by percentage of containment in this study. Percentage 
of containment or antimycobacterial activity is difficult to quan-
tify and may involve bacterial killing or induction of a non-
replicating state (we are unable to distinguish between these 2 
processes). The containment assay used in this study is a much 
more powerful, direct, and biologically meaningful outcome 
measure than inference from the biomarker-specific proxy 
markers of protection (cytokines, etc) that are often used in 
human studies but may merely represent epiphenomena rather 
than causality. Second, in the flow cytometry experiments, we 
used PPD rather than live Mtb. PPD is a Mtb lysate that is rou-
tinely used to activate and prime effector cells in in vitro studies 
to reciprocate live Mtb. Furthermore, PPD is routinely used in a 
diagnostic skin test to determine if a patient has been exposed 
to Mtb. The test measures a hypersensitive immune response to 
PPD. Therefore, the host immune modulatory capacity of PPD 
vs live Mtb would be expected to be similar. All our experiments 
were performed using PBMCs in vitro, which may not truly be 
representative of the immune milieu of the lung compartment in 
vivo. However, using lung cells was not possible due to feasibility, 
funding, and ethical constraints. It would have been interesting 
to investigate the causal relationship between Tregs and myco-
bacterial containment, given that we have previously shown that 
Tregs subvert mycobacterial containment in humans [17, 46]. 
However, this was not performed due to funding constraints.
In conclusion, our data indicate that MPA, but not NET-A, 
attenuates Mtb containment and antagonizes pathways asso-
ciated with protective host immunity through GR-mediated 
mechanisms. They highlight the potential risks of MPA usage in 
TB-endemic countries, possibly unlike NET-A. Clinical studies 
are urgently required to inform policy and delineate the role of 
MPA in the pathogenesis, acquisition, and dissemination of TB.
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Figure 4. Medroxyprogesterone acetate (MPA), but not norethisterone acetate (NET-A), reduces interferon gamma (IFN-γ) expression and cytotoxic T-lymphocyte (CTL) 
induction in CD8+ and CD4+ T cells. Peripheral blood mononuclear cells were treated with (n = 6) or without (n = 6) 12 µg/mL purified protein derivative (PPD) or in combination 
with 100 nM dexamethasone (n = 6), MPA (n = 6), NET-A (n = 6), and/or 1 µM RU486 (n = 6) for 7 days at 37°C. IFN-γ expression and CTL induction were assessed in the CD8+ 
and CD4+ T cells using flow cytometry. Error bars represent median and interquartile range. Data were analyzed for statistical significance by one-way analysis of variance 
with Dunnett post test, where * and ** indicate P < .05 and P < .01, respectively. Abbreviations: Dex, dexamethasone; IFN-γ, interferon gamma; MPA, medroxyprogesterone 
acetate; NET-A, norethisterone acetate; PPD, purified protein derivative.
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